Zobrazeno 1 - 10
of 16
pro vyhledávání: ''
Autor:
Hiroshi Uchi, Satoshi Fukushima, Yuki Yamamoto, Shigeto Matsushita, Hiroshi Kato, Yasuhiro Fujisawa, Ryo Amagai, Takeo Maekawa, Kentaro Ohuchi, Yusuke Muto, Yumi Kambayashi, Koji Yoshino, Taku Fujimura
Publikováno v:
Melanoma Research. 31:575-578
Patients with resected stage IIIB, IIIC and IIID melanomas have a high risk of recurrence. Therefore, an appropriate protocol for stage III melanoma is needed. Since adjuvant dabrafenib plus trametinib (D+T) combined therapy and anti-PD1 antibody (Ab
Autor:
Gina Klee, Patrick Terheyden, Jonas K. Kurzhals, Victoria Hagelstein, Detlef Zillikens, Ewan A. Langan, Andreas Recke
Publikováno v:
Melanoma Research. 31:464-471
Combined immunotherapy is associated with a significant risk of severe and potentially fatal immune-related adverse events (irAEs). Therefore, we retrospectively analyzed the side profile and efficacy of low-dose ipilimumab (1 mg/kg, IPI1) combined w
Autor:
Gina Klee, Victoria Hagelstein, J.K. Kurzhals, Detlef Zillikens, Patrick Terheyden, Ewan A. Langan
Publikováno v:
Melanoma research. 32(5)
Despite the dramatic improvement in both overall survival (OS) and progression-free survival (PFS) in patients with metastatic melanoma treated with immune checkpoint inhibitors, up to 60% will develop treatment resistance and 50% will die from their
Autor:
Sarah Guégan, Selim Aractingi, C. Lheure, Gabrielle Goldman-Lévy, Nathalie Franck, Nicolas Dupin, Sandra Huynh, Nora Kramkimel
Publikováno v:
Melanoma Research. 30:317-320
Combined BRAF and MEK inhibition is one of the first-line treatment strategies for patients with advanced BRAF-mutant melanoma. Sarcoid-like reactions (SLRs) have occasionally been described with melanoma systemic treatments such as immunotherapy or
Autor:
Reinhard Dummer, Valerie C Amann, Anita Giobbie-Hurder, Simone M. Goldinger, Donald P. Lawrence, Lisa Zimmer, Joanna Mangana, Elisabeth Livingstone, Joshua Z. Drago, Tianqi Chen, Alfred Zippelius, Marco Siano, Ryan J. Sullivan
Publikováno v:
Melanoma Research. 29:65-69
BRAF and MEK kinase inhibitors can be highly effective in treating BRAF-mutant melanomas, but their safety and activity in patients with active/symptomatic brain metastases are unclear. We sought to shed light on this open clinical question. We condu
Autor:
Christian U. Blank, Johannes V. Van Thienen, Dieta Brandsma, John B. A. G. Haanen, Willem Boogerd, Marnix H Geukes Foppen
Publikováno v:
Melanoma Research. 28:126-133
Patients with brain metastases (BM) from melanoma have an overall survival (OS) of 2-6 months after whole-brain radiotherapy. Targeted therapy (TT) is an effective treatment for BRAF-mutated metastatic melanoma. Moreover, recent studies indicate intr
Autor:
Alan G. Palestine, Anna G Mackin, Jennifer L. Patnaik, Rene Gonzalez, William A. Robinson, Amanda L Dinsmore, Paula E. Pecen
Publikováno v:
Melanoma research. 29(5)
The aim of this study was to describe inflammatory side effects in patients treated with BRAF and MEK inhibitors at a single tertiary care institution. This was a retrospective chart review of patients prescribed single-agent or combination BRAF and
Autor:
Helena Linardou, Dimitrios Bafaloukos, Dimosthenis Tsoutsos, Apostolos Laskarakis, A. Tarampikou, Helen Gogas, Theodoros N. Sergentanis, Amalia Anastasopoulou, George Papaxoinis, Panagiotis T. Diamantopoulos
Publikováno v:
Melanoma research. 29(4)
This retrospective cohort study assessed the prognostic significance of distant metastasis-free interval (DMFI) in patients with relapsed BRAF-mutant melanoma treated with BRAF with or without MEK inhibitors (BRAFi ± MEKi). Patients with a DMFI of u
Autor:
Marcin Rajczykowski, Łukasz Galus, Marek Ziobro, Anna Klimczak, Bożena Cybulska-Stopa, Anna Mariuk-Jarema, Iwona Ługowska, Rafał Suwiński, Robert Dziura, Paweł Teterycz, Sławomir Falkowski, Tomasz Świtaj, Jacek Mackiewicz, Katarzyna Kozak, Paulina Jagodzińska-Mucha, Piotr Rutkowski, Hanna Koseła-Paterczyk, Anna M. Czarnecka
Publikováno v:
Melanoma research. 28(5)
Neutrophil-to-lymphocyte ratio (NLR) has been shown to be prognostic in several solid malignancies. There are limited data regarding its value during novel therapies in patients with melanoma. The aim of the study was to assess the practical utility
Autor:
Alexander Guminski, Dariush Douraghi-Zadeh, Alexander M. Menzies, Paolo A. Ascierto, Serigne Lo, Timmothy Harrington, Malinda Itchins, Meredith Oatley, Antonio M. Grimaldi, Richard Maher
Publikováno v:
Melanoma research. 27(3)
Metastatic uveal melanoma is a rare malignancy with a poor prognosis. To date, systemic therapy has been ineffective; however, there are few data on the benefits of anti-CTLA4 or anti-PD-1 antibodies in sequence with liver-directed therapy. A retrosp